Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing

被引:10
|
作者
Jaffre, Jeremy [1 ,2 ]
Aubry, Alexandra [1 ,2 ]
Maitre, Thomas [1 ]
Morel, Florence [1 ,2 ]
Brossier, Florence [1 ,2 ]
Robert, Jerome [1 ,2 ]
Sougakoff, Wladimir [1 ,2 ]
Veziris, Nicolas [1 ,2 ,3 ]
机构
[1] Sorbonne Univ, Grp Hosp Univ, Hop Pitie Salpetriere, AP HP,Ctr Natl Reference Mycobacteries & Resistan, Paris, France
[2] Sorbonne Univ, INSERM, Cimi Paris, Ctr Immunol & Malad Infect,U1135, Paris, France
[3] Sorbonne Univ, Grp Hosp Univ, Hop St Antoine, AP HP, Paris, France
关键词
drug susceptibility testing; Mycobacterium avium complex; SLOMYCO Sensititre; Mueller Hinton; clarithromycin; amikacin; IN-VITRO ACTIVITY; RANDOMIZED-TRIAL; LUNG-DISEASE; CLARITHROMYCIN; THERAPY; COMBINATION; ETHAMBUTOL; RIFABUTIN; REGIMENS; AMIKACIN;
D O I
10.3389/fmicb.2020.00081
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Clinical and Laboratory Standards Institute recommends the use of Mueller Hinton (MH) medium to perform drug susceptibility testing (DST) of Mycobacterium avium complex (MAC) using the microdilution method. For MAC, there has been no study on the impact of media on the determination of minimum inhibitory concentrations (MICs) of antibiotics other than clarithromycin. This study aimed at determining the impact of two media used for DST of MAC and at augmenting the number of pertinent MICs for MAC species encountered in clinical practice. MICs of antibiotics used for the treatment of MAC infections were determined for 158 clinical MAC isolates (80 M. avium, 40 M. intracellulare, 35 M. chimaera, two M. yongonense and one M. timonense) in MH and 7H9 broths using the SLOMYCO Sensititre(TM) system (TREK Diagnostic Systems, East Grinstead, United Kingdom). The modal MICs determined in both media were the same for linezolid, moxifloxacin, rifabutin and amikacin but not for clarithromycin, rifampin and ethambutol. The kappa test for MICs converted to susceptibility categories showed an excellent agreement for clarithromycin, a moderate agreement for linezolid and a weak agreement for moxifloxacin and amikacin. For amikacin, 7H9 allowed a better distinction (fewer intermediate strains) of wild-type populations than MH. Existing breakpoints for linezolid and moxifloxacin are spread through the distribution of MICs for wild-type populations. The only breakpoints that can be used rationally are those for amikacin and clarithromycin. For amikacin, 7H9 performs better than MH, whereas both media perform equally for clarithromycin. Given that testing in 7H9, as opposed to MH, allows easier MIC measurements and yields greater reproducibility, we propose the use of 7H9 medium for DST of MAC.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Variability of Mycobacterium avium Complex Isolates Drug Susceptibility Testing by Broth Microdilution
    Zimenkov, Danila
    ANTIBIOTICS-BASEL, 2022, 11 (12):
  • [2] New trends in the drug therapy of localized and disseminated Mycobacterium avium complex infection
    Sesin, GP
    Manzi, SF
    Pacheco, R
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (21) : 2585 - 2590
  • [3] Clofazimine susceptibility testing of Mycobacterium avium complex and Mycobacterium abscessus: a meta-analysis study
    Hajikhani, Bahareh
    Nasiri, Mohammad Javad
    Hosseini, Sareh Sadat
    Khalili, Farima
    Karimi-Yazdi, Mohammadmahdi
    Hematian, Ali
    Nojookambari, Neda Yousefi
    Goudarzi, Mehdi
    Dadashi, Masoud
    Mirsaeidi, Mehid
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 26 : 188 - 193
  • [4] In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex
    Brown-Elliott, Barbara A.
    Philley, Julie V.
    Griffith, David E.
    Thakkar, Foram
    Wallace, Richard J., Jr.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (02)
  • [5] Two-drug versus three-drug regimens for treating Mycobacterium avium complex infection: A systematic review and meta-analysis
    Nguyen, Van-Dong
    Duong, Hai
    Lee, Ming-Chia
    Chen, Jin-Hua
    Huang, Wei-Chang
    Chen, Hsiao-En
    Lin, Jung-Chun
    Wang, Jann-Yuan
    Lee, Chih-Hsin
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2025, 18 (05)
  • [6] Use of potassium tellurite for rapid-drug susceptibility testing of Mycobacterium avium complex
    Afghani, B
    Fujiyama, D
    JOURNAL OF INVESTIGATIVE MEDICINE, 2001, 49 (03) : 292 - 296
  • [7] Identification and drug susceptibility testing of the subspecies of Mycobacterium avium complex clinical isolates in mainland China
    Li, Yuanchun
    Liu, Chunfa
    Ma, Aijing
    He, Wencong
    Qiu, Qian
    Zhao, Yanlin
    Li, Yanming
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2022, 31 : 90 - 97
  • [8] Therapeutic Drug Monitoring in the Treatment of Mycobacterium avium Complex Lung Disease
    Koh, Won-Jung
    Jeong, Byeong-Ho
    Jeon, Kyeongman
    Lee, Soo-Youn
    Shin, Sung Jae
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (08) : 797 - 802
  • [9] Bedaquiline susceptibility testing of Mycobacterium abscessus complex and Mycobacterium avium complex: A meta-analysis study
    Wang, Ming
    Men, Peixuan
    Zhang, Weihe
    Wu, Jing
    Gu, Yuzhen
    Wang, Fen
    Huang, Hairong
    Yu, Xia
    Duan, Hongfei
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2024, 37 : 135 - 140
  • [10] Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system
    Ozawa, Takuya
    Namkoong, Ho
    Takaya, Risako
    Takahashi, Yusuke
    Fukunaga, Koichi
    Enoki, Yuki
    Taguchi, Kazuaki
    Kizu, Junko
    Matsumoto, Kazuaki
    Hasegawa, Naoki
    BMC INFECTIOUS DISEASES, 2022, 22 (01)